Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked conscientiously but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the past several shares of mine. My first CytoDyn post, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire job interview which I came away with a bad impression of the company.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the technology and associated intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) and also the very first brand new drug application endorsement ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and numerous therapies, it has this single therapies as well as a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active company with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations in addition to multiple publications.

Could all this be smoke and mirrors? That is a question I’ve been asking myself through the really beginning of my interest in this organization. Judging with the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *